Roche

(IN BRIEF) Roche has announced positive late-breaking data from the Phase III OCARINA II study, which demonstrates the effectiveness of OCREVUS as a twice-yearly, 10-minute subcutaneous injection for patients with relapsing or primary progressive multiple sclerosis (RMS or PPMS). The … Read the full press release →

(IN BRIEF) Roche has reported positive outcomes from the RAINBOWFISH study, an investigation into the efficacy and safety of Evrysdi® (risdiplam) in babies with pre-symptomatic spinal muscular atrophy (SMA). The study, which included 26 infants aged from birth to six … Read the full press release →

(IN BRIEF) BioNTech and the Coalition for Epidemic Preparedness Innovations (CEPI) have entered into a strategic partnership to develop an mRNA-based vaccine, BNT166, for the prevention of mpox (formerly monkeypox), an infectious disease that can have severe and life-threatening complications. … Read the full press release →

(IN BRIEF) Pfizer and BioNTech have received a recommendation for marketing authorization from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for their Omicron XBB.1.5-adapted monovalent COVID-19 vaccine. The recommendation includes the administration of a single … Read the full press release →

(IN BRIEF) BioNTech SE, a biopharmaceutical company, has appointed James Ryan as Chief Legal Officer (CLO) and a member of the Management Board, effective from September 1, 2023. In this role, Ryan will oversee the company’s corporate legal strategy, global … Read the full press release →